Gene · 5607
Papers1,405
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 1,405
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The Circadian-Melatonin Axis in Bone Remodeling: Receptor-Dependent Signaling, Receptor-Independent Actions, and Translational Constraints. | Biomolecules | 2026 | 42793064 | PubTator, text mining | PubMed |
| Folic acid polyglutamylation triggers MAP2K5 signaling to induce adipocyte lipid catabolism. | bioRxiv | 2026 | 42779987 | PubTator, text mining | PubMed |
| Berberine Attenuates Hypertrophic Phenotype in RAF1-Mutant Induced Pluripotent Stem Cell-Derived Cardiomyocytes through Suppression of ERK5-Cyclin D1 Signaling. | Cardiovasc Drugs Ther | 2026 | 42667574 | PubTator, text mining | PubMed |
| Educational attainment and diabetes risk: triangulation evidence from UK Biobank prospective cohort, NHANES 2011-2018, and cross-trait genomics analyses. | Front Endocrinol (Lausanne) | 2026 | 42434303 | PubTator, text mining | PubMed |
| Compound Danshen Dripping Pills retards the progression of cerebral cavernous malformations via strengthening vascular integrity and ameliorating inflammatory response. | Phytomedicine | 2026 | 42341528 | PubTator, text mining | PubMed |
| Integration of Brain Proteomes and Genome-Wide Association Data Identifies GLO1 as a Candidate Causal Gene and Therapeutic Target for Restless Legs Syndrome. | Int J Mol Sci | 2026 | 42196425 | PubTator, text mining | PubMed |
| A systematic review on the impact of type 2 diabetes on Leydig and Sertoli cells: Molecular mechanisms and functional consequences. | Diabetes Metab Syndr | 2026 | 42097114 | PubTator, text mining | PubMed |
| Molecular and Cellular Mechanisms of Anti-Obesity Agents: An Integrative Review. | FASEB J | 2026 | 42036909 | PubTator, text mining | PubMed |
| Activation of Nerve Growth Factor signaling limits the response to lenvatinib in hepatocellular carcinoma. | Signal Transduct Target Ther | 2026 | 41946693 | PubTator, text mining | PubMed |
| AXL is a novel ERK5/KLF4 target in MEK inhibitor-treated melanoma. | Neoplasia | 2026 | 41916083 | PubTator, text mining | PubMed |
| A different MAPK, ERK5 plays a critical role in cell specification and differentiation. | Biochem Biophys Rep | 2026 | 41909153 | PubTator, text mining | PubMed |
| Dose-Dependent Inhibition of Protein Glycosylation Reveals Crosstalk between Glycosylation and Phosphorylation in EGF Signaling Pathways. | Anal Chem | 2026 | 41843583 | PubTator, text mining | PubMed |
| VCAN Is Essential for ERK5-Driven Tumorigenesis in Soft Tissue Sarcoma. | Int J Biol Sci | 2026 | 41800245 | PubTator, text mining | PubMed |
| Editorial: Challenges and opportunities in tumor metabolomics. | Front Mol Biosci | 2026 | 41756027 | PubTator, text mining | PubMed |
| Foundations of an Ovine Model of Fragile X Syndrome. | Genes (Basel) | 2026 | 41751536 | PubTator, text mining | PubMed |
| A Multiomic Approach Integrating Genomic and Metabolomic Data Highlights Colorectal Cancer Pathways. | J Proteome Res | 2026 | 41603468 | PubTator, text mining | PubMed |
| Mechanistic study of glutamine metabolic reprogramming driving non-small cell lung cancer progression via the FGF17-FGFR4 axis mediating epithelial-mesenchymal transition. | Front Mol Biosci | 2025 | 41551579 | PubTator, text mining | PubMed |
| Integration of human ERKs and DUSPs into the yeast cell wall integrity pathway. | Sci Rep | 2025 | 41453955 | PubTator, text mining | PubMed |
| Protein Posttranslational Modifications in Glioma Stem Cells. | Biol Pharm Bull | 2025 | 41320273 | PubTator, text mining | PubMed |
| Structural basis for MEKK2 dimerization and substrate recognition. | Nat Commun | 2025 | 41318559 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5607/papers